Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure

EliquisNegative

AI Analysis

Summary

Pfizer announced an additional $2.5 billion in cuts across R&D and manufacturing, with total restructuring costs of $6 billion primarily occurring between 2027-2029, as the company addresses post-COVID challenges and patent expirations for major products including Eliquis.

Importance:5/10

Sentiment:

-0.70

restructuringcost_reductionR&D cutsmanufacturing cutspatent_cliffpost-COVID impact

Related Companies

$PFE

Read the original article

Published by BioSpace on August 4, 2026 1:22 PM

Read Original